These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16149296)

  • 41. Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer.
    Wang MZ; Li LY; Wang SL; Zhang XT; Zhong W; Zhang L
    Chin Med J (Engl); 2006 Jan; 119(1):63-8. PubMed ID: 16454984
    [No Abstract]   [Full Text] [Related]  

  • 42. Gefitinib. Still no convincing results in non-small cell lung cancer.
    Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
    [No Abstract]   [Full Text] [Related]  

  • 43. Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal.
    Dahlberg SE; Gray RJ; Johnson BE
    J Clin Oncol; 2008 Sep; 26(26):4233-5. PubMed ID: 18779608
    [No Abstract]   [Full Text] [Related]  

  • 44. [Mechanism of action and preclinical development of afatinib].
    Diz Taín P; González AL; García-Palomo A
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():7-11. PubMed ID: 27426242
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictors of clinical response of non-small cell cancer to gefitinib.
    Ardizzoni A; Tiseo M
    JAMA; 2004 Apr; 291(13):1563; author reply 1563-4. PubMed ID: 15069041
    [No Abstract]   [Full Text] [Related]  

  • 46. Reversal of male-pattern baldness, hypertrichosis, and accelerated hair and nail growth in patients receiving benoxaprofen.
    Fenton DA; English JS; Wilkinson JD
    Br Med J (Clin Res Ed); 1982 Apr; 284(6324):1228-9. PubMed ID: 6803912
    [No Abstract]   [Full Text] [Related]  

  • 47. An unusual terminal hair growth on the nose tip associated with gefitinib therapy.
    Kim SY; Choi HJ; Park HJ; Lee JY; Cho BK
    Br J Dermatol; 2007 May; 156(5):1087-8. PubMed ID: 17388923
    [No Abstract]   [Full Text] [Related]  

  • 48. Gefitinib maintenance in stage III non-small-cell lung cancer.
    Stewart DJ
    J Clin Oncol; 2008 Oct; 26(29):4849-50; author reply 4850-1. PubMed ID: 18779595
    [No Abstract]   [Full Text] [Related]  

  • 49. Gefitinib for refractory advanced non-small-cell lung cancer.
    Moriguchi H; Kim TY; Sato C
    Lancet; 2006 Jan; 367(9507):299-300. PubMed ID: 16443032
    [No Abstract]   [Full Text] [Related]  

  • 50. Gefitinib: phoenix from the flames.
    Lancet Oncol; 2009 Aug; 10(8):737. PubMed ID: 19647191
    [No Abstract]   [Full Text] [Related]  

  • 51. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.
    Beau-Faller M; Blons H; Domerg C; Gajda D; Richard N; Escande F; Solassol J; Denis MG; Cayre A; Nanni-Metellus I; Olschwang S; Lizard S; Piard F; Pretet JL; de Fraipont F; Bièche I; de Cremoux P; Rouquette I; Bringuier PP; Mosser J; Legrain M; Voegeli AC; Saulnier P; Morin F; Pignon JP; Zalcman G; Cadranel J
    J Mol Diagn; 2014 Jan; 16(1):45-55. PubMed ID: 24183959
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
    J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC).
    Bearz A; Fratino L; Spazzapan S; Berretta M; Giacalone A; Simonelli C; Tirelli U
    Lung Cancer; 2007 Jan; 55(1):125-7. PubMed ID: 17064811
    [No Abstract]   [Full Text] [Related]  

  • 54. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
    Viswanathan A; Pillot G; Govindan R
    Lung Cancer; 2005 Dec; 50(3):417-8. PubMed ID: 16129510
    [No Abstract]   [Full Text] [Related]  

  • 56. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
    Kim ES; Hirsh V; Mok T; Socinski MA; Gervais R; Wu YL; Li LY; Watkins CL; Sellers MV; Lowe ES; Sun Y; Liao ML; Osterlind K; Reck M; Armour AA; Shepherd FA; Lippman SM; Douillard JY
    Lancet; 2008 Nov; 372(9652):1809-18. PubMed ID: 19027483
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gefitinib in non-small cell lung carcinoma: a case report of an unusual side effect and complete response in advanced disease.
    Laterza MM; Chiurazzi B; Brangi M; Riccardi F; Cartenì G
    Tumori; 2013; 99(1):3e-5e. PubMed ID: 23549019
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gefitinib versus cetuximab in lung cancer: round one.
    Minna JD; Peyton MJ; Gazdar AF
    J Natl Cancer Inst; 2005 Aug; 97(16):1168-9. PubMed ID: 16106015
    [No Abstract]   [Full Text] [Related]  

  • 59. Gefitinib versus docetaxel for previously treated NSCLC--letter.
    Tassinari D; Lazzari-Agli L; Tombesi P; Sartori S
    Clin Cancer Res; 2011 Jul; 17(13):4610; author reply 4611. PubMed ID: 21712456
    [No Abstract]   [Full Text] [Related]  

  • 60. Increasing osteoblastic lesions as a manifestation of a major response to gefitinib.
    Garfield D
    J Thorac Oncol; 2006 Oct; 1(8):859-60. PubMed ID: 17409972
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.